ClinicalTrials.gg
TerminatedNCT02527681Updated Jun 5, 2023Results posted

Pharmacokinetics and Safety of Ceftobiprole in Neonates and Infants up to 3 Months Treated With Systemic Antibiotics

A Phase 1 interventional study of Ceftobiprole medocaril in Bacterial Infections, sponsored by Basilea Pharmaceutica. Terminated at 14 sites in 6 countries. Open to participants aged Up to 3 Months. Per ClinicalTrials.gov, last updated 2023-06-05.

Sponsored by Basilea Pharmaceutica · Phase 1, Interventional, and Treatment

Why this study was terminated
on July 07, 2020 due to slow enrollment; there were no safety concerns.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
15
Allocation
Not applicable
Ages
Up to 3 Months
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 181 studies in Bacterial Infections with a site in United States — 12 open to participants now, 15 under way, 2 of them phase 3. Bacterial Infections · United States.

Enrollment
136th of 151
15 · median 62
Started
2016
with 12 others
Phase 1
66 of 181
2 open now
Registered
94th of 181
by date

Among the 181 studies in Bacterial Infections with a site in United States, this one is the 136th largest by enrollment of the 151 interventional ones that give a count, is one of 13 that started in 2016, is one of 66 in phase 1, and was the 94th registered.

Bacterial Infections

585 studies on the registry are indexed under Bacterial Infections; 84 are open to participants now.

Browse Bacterial Infections studies →

Open to participants now

12 of the 181 studies in Bacterial Infections with a site in United States are open now. Recruiting first, the newest first:

7 more — sign in →

All 12 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 57 Bacterial Infections studies recruiting now, 38 (67%) set no upper age limit and 14 (25%) stop at 75 or younger; 19 take children under 18; 6 take healthy volunteers.

This study: Up to 3 Months · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 181 studies in Bacterial Infections with a site in United States, or all of them as a file.
02

Study summary

This study characterized the pharmacokinetics and safety of a single dose of ceftobiprole in neonates and infants aged ≤ 3 months.

03

Conditions studied

  • Bacterial Infections

Browse trials for

04

Who can participate

Ages eligible
Up to 3 Months
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Neonates and infants ≤3 months, with gestational age ≥28 weeks
  • Documented or presumed (or at risk of) bacterial infections, and currently receiving antibiotic treatment
  • Expected to survive beyond the first 7 days after enrollment
  • Sufficient vascular access to receive study drug, and to allow blood sampling at a site separate from the study drug infusion site
  • Parent's / legally acceptable representative's to participate in the study

Exclusion criteria

Exclusion Criteria:

  • Major birth defect or malformation syndrome
  • Proven presence of an immunodeficiency
  • or other congenital viral or fungal infection
  • Significant laboratory abnormalities including: hematocrit \<20%; \<0.5x10⁹/L; count \< 50x10⁹/L; or aspartate aminotransferase >3 times the age-specific
  • Impaired renal function or known significant renal disease
  • Any condition which would make the subject or caregiver, in the opinion of the investigator, unsuitable for the study
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
15 participants (actual)

Study arms

  • Experimental
    Ceftobiprole

    Ceftobiprole medocaril is the water-soluble prodrug of ceftobiprole, an advanced-generation cephalosporin developed for intravenous administration. Ceftobiprole is characterized by potent, broad-spectrum antimicrobial activity against both Gram-positive and Gram-negative pathogens.

    Drug: Ceftobiprole medocaril

Interventions

  • Ceftobiprole medocaril was administered as a single intravenous infusion, with a bodyweight-adjusted volume, at a constant rate over 4 hours. The ceftobiprole dose was 7.5 mg/kg, which corresponds to 10.0 mg ceftobiprole medocaril.

    Also known as: ceftobiprole

06

What researchers measure

Primary outcomes

  1. Cmax

    The maximum observed plasma concentration (Cmax)

    Time frame: Blood samples for pharmacokinetic (PK) analysis were obtained pre-dose, and at 2, 4, 6, 8, and 12 hours after the start of dosing.

  2. Tmax

    The time of maximum observed plasma concentration (Tmax)

    Time frame: Blood samples for PK analysis were obtained pre-dose, and at 2, 4, 6, 8, and 12 hours after the start of dosing.

  3. AUC0-last

    The area under the plasma concentration-time curve from time zero to the time of the last measurable concentration (AUC0-last)

    Time frame: Blood samples for PK analysis were obtained pre-dose, and at 2, 4, 6, 8, and 12 hours after the start of dosing.

  4. T>MIC of 4 mg/L

    The duration of time after dose for which free-drug concentrations remained above a value of 4 mg/L (T\>MIC of 4 mg/L)

    Time frame: Blood samples for PK analysis were obtained pre-dose, and at 2, 4, 6, 8, and 12 hours after the start of dosing.

07

Results

Posted Jan 6, 2021

Participant flow

Participant flow — Overall Study
MilestoneCeftobiprole ITT/Safety Population
Started15
Completed15
Not completed0

Outcome measures

PrimaryCmax

The maximum observed plasma concentration (Cmax)

Time frame:
Blood samples for pharmacokinetic (PK) analysis were obtained pre-dose, and at 2, 4, 6, 8, and 12 hours after the start of dosing.
Reported as:
Median · μg/mL
Cmax
μg/mLCeftobiprole PK Population
Cmax11.2 (8.68 to 32.6)
PrimaryTmax

The time of maximum observed plasma concentration (Tmax)

Time frame:
Blood samples for PK analysis were obtained pre-dose, and at 2, 4, 6, 8, and 12 hours after the start of dosing.
Reported as:
Median · hours
Tmax
hoursCeftobiprole PK Population
Tmax4.00 (4.00 to 4.00)
PrimaryAUC0-last

The area under the plasma concentration-time curve from time zero to the time of the last measurable concentration (AUC0-last)

Time frame:
Blood samples for PK analysis were obtained pre-dose, and at 2, 4, 6, 8, and 12 hours after the start of dosing.
Reported as:
Median · μg•hours/mL
AUC0-last
μg•hours/mLCeftobiprole PK Population
AUC0-last60.6 (49.1 to 126.0)
PrimaryT>MIC of 4 mg/L

The duration of time after dose for which free-drug concentrations remained above a value of 4 mg/L (T\>MIC of 4 mg/L)

Time frame:
Blood samples for PK analysis were obtained pre-dose, and at 2, 4, 6, 8, and 12 hours after the start of dosing.
Reported as:
Median · hours
T>MIC of 4 mg/L
hoursCeftobiprole PK Population
T>MIC of 4 mg/L5.40 (3.77 to 8.13)

Adverse events

Collected over After start of study drug administration through the follow-up visit at study Day 7±3, relevant worsening of a subject's status was to be recorded as an adverse event (AE).. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Ceftobiprole ITT/Safety Population0/15 (0%)2/15 (13.3%)4/15 (26.7%)
Most frequent serious events
Most frequent serious events
EventCeftobiprole ITT/Safety Population
Diaphragmatic herniaGastrointestinal disorders1/15
Cerebral infarctionNervous system disorders1/15
Most frequent other events
Most frequent other events
EventCeftobiprole ITT/Safety Population
Dermatitis diaperSkin and subcutaneous tissue disorders2/15
Drug DependencePsychiatric disorders1/15
ErythemaSkin and subcutaneous tissue disorders1/15

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Ceftobiprole ITT/Safety Population
<=18 years15
Between 18 and 65 years0
>=65 years0
Age, Continuous
Age, Continuous(days)Ceftobiprole ITT/Safety Population
Median13 (8 to 43)
Sex: Female, Male
Sex: Female, Male(Participants)Ceftobiprole ITT/Safety Population
Female5
Male10
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Ceftobiprole ITT/Safety Population
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander1
Black or African American1
White13
More than one race0
Unknown or Not Reported0
08

Study locations

14 sites
  • Loma Linda University Medical Center
    Loma Linda, California 92354, United States
  • University of Southern California
    Los Angeles, California 90089, United States
  • University of California Los Angeles
    Los Angeles, California 90095, United States
  • Beacon Children's Hospital
    South Bend, Indiana 46601, United States
  • Norton Children's Hospital
    Louisville, Kentucky 40202, United States
  • Duke University Hospital
    Durham, North Carolina 27705, United States
  • University of Pittsburgh Medical Center Cancer Center at Magee-Womens Hospital
    Pittsburgh, Pennsylvania 15224, United States
  • The University of Texas Health Science Center at Houston
    Houston, Texas 77030, United States
  • West Virginia University School of Medicine
    Morgantown, West Virginia 26506-9214, United States
  • UZ Leuven
    Leuven, Belgium
  • Klinikum der Universität München
    Munich, Germany
  • Children Clinical University Hospital
    Riga, Latvia
  • Vilnius University Children's Hospital
    Vilnius, Lithuania
  • University Children's Hospital of Kraków
    Kraków, Poland
09

References and documents

Publications

  • Rubino CM, Polak M, Schropf S, Munch HG, Smits A, Cossey V, Tomasik T, Kwinta P, Snariene R, Liubsys A, Gardovska D, Hornik CD, Bosheva M, Ruehle C, Litherland K, Hamed K. Pharmacokinetics and Safety of Ceftobiprole in Pediatric Patients. Pediatr Infect Dis J. 2021 Nov 1;40(11):997-1003. doi: 10.1097/INF.0000000000003296. PubMed 34533489 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2016 to primary completion in Feb 2020, 39 months.

Results were first posted in Jan 2021, 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 5, 2015
First posted
Aug 19, 2015
StartActual
Nov 22, 2016
Primary completionActual
Feb 25, 2020
CompletionActual
Feb 25, 2020
Results first posted
Jan 6, 2021
Last update
Jun 5, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 5, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02527681
Responsible party
Sponsor
First posted
Aug 19, 2015
Start date
Nov 22, 2016
Primary completion
Feb 25, 2020
Completion
Feb 25, 2020
Results posted
Jan 6, 2021
Last update
Jun 5, 2023

Study contacts

Marc Engelhardt, MD
study director · Basilea Pharmaceutica

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in May 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ceftobiprole medocaril

Start the discussion